Burnet opposes Gene Patenting Bill

Burnet Institute

20 April, 2011

In a letter to the inquiry Burnet Institute Director and CEO Professor Brendan Crabb said the Bill could impact funding for development of medical research technologies.

“This could potentially affect researchers working on those projects and patients who would miss out from access to these technologies,” he said in the letter.

The ability to move medical technologies developed for the detection, prevention and treatment of HIV, hepatitis, malaria and cancer from bench to the bedside could also be in jeopardy if this Bill is passed.

Professor Crabb ultimately asked the inquiry to reject the Bill saying it could have “some serious consequences for our Institution’s continued research and development and for medical research in general.”

Burnet Institute’s submission has been made a public document.

Contact Details

For more information in relation to this news article, please contact:

Professor Brendan Crabb AC

Director and CEO; Co-Head Malaria Research Laboratory; Chair, Victorian Chapter of the Association of Australian Medical Research Institutes (AAMRI)




Subscribe to News

Subscribe to receive our latest news: